Embryo-Peptide Composition Dissociation for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions based on heterologous embryonic extracts for oral administration face challenges in achieving high bioavailability due to the dilution of embryo-peptides and variable physiological responses, primarily because they fail to dissociate growth factors from their soluble receptors effectively, leading to inconsistent absorption and metabolic regulation.
Innovation Solution
A process that includes dissociating peptide growth factors from their soluble receptors using Zn2+ ions in concentrated solutions, followed by enzymatic hydrolysis and ultrafiltration to enrich embryo-peptides, combined with specific additives like maltodextrin, selenium yeast, and cationic peptides to enhance bioavailability and absorption through the intestinal barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional extraction methods are used for embryo-peptides, then the extraction process is simple, but the bioavailability is low due to dilution and failure to dissociate growth factors from soluble receptors
Solution Approach 1:
The extraction process is divided into distinct stages: initial extraction, ultrafiltration to separate by molecular weight, and specific dissociation of growth factors from soluble receptors. This segmentation allows each step to be optimized independently, improving overall bioavailability while maintaining manageable process complexity through systematic breakdown of the extraction workflow.
Solution Approach 2:
The patent applies preliminary actions by pre-dissociating growth factors from their soluble receptors before final formulation, and by using ultrafiltration to pre-concentrate embryo-peptides. These preliminary steps ensure that the active components are in the optimal form for absorption before administration, thereby improving bioavailability without requiring complex post-processing.
2Reliability
If growth factors are not dissociated from soluble receptors, then the extraction process is straightforward, but the physiological response variability is high
Solution Approach 1:
The patent uses specific intermediaries to facilitate the dissociation of growth factors from soluble receptors. By introducing intermediary substances or conditions that selectively break these associations, the process achieves consistent physiological responses while keeping the dissociation step manageable through the use of well-characterized intermediary agents.
Solution Approach 2:
The dissociation process utilizes controlled changes in parameters such as pH, ionic strength, or temperature to selectively break the bonds between growth factors and soluble receptors. By adjusting these parameters within specific ranges, the patent achieves reliable dissociation and consistent physiological responses without requiring overly complex process control.
3Reliability
If embryo-peptides are not enriched, then the formulation is simpler, but the absorption through intestinal barrier is insufficient
Solution Approach 1:
The patent applies local quality by concentrating embryo-peptides to high levels in specific fractions through ultrafiltration, creating regions of high peptide concentration that are optimized for absorption. This localized enrichment ensures sufficient absorption through the intestinal barrier while keeping the overall formulation manageable by focusing complexity only where needed.
Solution Approach 2:
The enriched embryo-peptide formulation is combined with complementary materials that enhance absorption through the intestinal barrier. This composite approach improves absorption efficiency by synergistically combining embryo-peptides with absorption-enhancing carriers or adjuvants, while maintaining formulation simplicity through the use of well-established composite material systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves increased bioavailability of embryo-peptides, leading to reproducible metabolic re-equilibration and regulation of disorders by stimulating endocytosis, reducing variability in physiological responses, and promoting long-term metabolic balance.
Implementation Method 1
dissociating peptide growth factors from their soluble receptors using Zn2+ ions in concentrated solutions
Implementation Method 2
enzymatic hydrolysis and ultrafiltration to enrich embryo-peptides
Implementation Method 3
ultrafiltration to enrich embryo-peptides
Implementation Method 4
stimulating endocytosis, reducing variability in physiological responses
Data Source
AI summary
The invention refers to a composition standardized in heterologous embryo-peptides, used as a dietary supplement and to a process for its obtainment. The composition consists of heterologous embryonic extract, standardized in embryo-peptides, maltodextrin, selenium yeast, chromium yeast, zinc chelated in embryo-peptides, pyridoxine, mixture of cationic peptides, formed by enzymatic hydrolysis of vitellus and egg white remaining after chicken embryo harvesting, with antitrypsin and endocytosis promoting activity, sodium taurocholate, expanded silicon dioxide, magnesium stearate, methylparaben and propylparaben. The process of obtainment consists of the following steps: obtaining and disintegration of biological material, diluting with sterile water, homogenization and dissociation of embryonic growth factors from their soluble receptors; embryo-peptides concentration through tangential ultrafiltration; embryo-protein denaturation and mixing of embryo-peptides with denatured proteins; obtainment of cationic peptides and their addition and of others components over the mixture embryo peptides-embryo proteins, homogenization and spray-drying of the final mixture.